Intec Pharma
Controlled Drug-delivery Technology for the Upper Gastrointestinal Tract
Company Overview
Snapshot
Founded in October 2000 by Zvi Joseph, Intec Pharma operates with 1–10 employees and has raised $80.4 million across 5 funding rounds from 5 investors. The company was delisted from NASDAQ and TASE in August 2021 following its merger with Decoy Biosystems.
Business overview
Intec Pharma is a clinical-stage biopharmaceutical company specializing in drug development using its proprietary Accordion Pill (AP) platform technology. This oral drug-delivery system is engineered to enhance the efficacy and safety of both existing and developing drugs through efficient gastric retention and specific release mechanisms. The company's pipeline includes Accordion Pill Carbidopa/Levodopa for Parkinson's disease and AP-cannabinoids for indications such as cancer pain and opioid-sparing pain management, operating within the Health Tech &.
Strategic signal
In August 2021, Intec Pharma completed its merger with Decoy Biosystems, leading to its delisting from both NASDAQ and TASE. This strategic move indicates a significant pivot for the company, transitioning from an independent entity to an integrated part of Decoy Biosystems, and signals a shift in its operational and strategic focus within the biopharmaceutical landscape.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant corporate event for Intec Pharma in 2021?
- In August 2021, Intec Pharma completed a merger with Decoy Biosystems, which led to its delisting from NASDAQ and TASE.
- What was the outcome of Intec Pharma's Parkinson's trial in July 2019?
- In July 2019, Intec Pharma experienced a setback as its Parkinson's trial failed, leading to a significant drop in its stock value.
- What was a key development for Intec Pharma's Accordion Pill technology in July 2019?
- In July 2019, Intec Pharma announced the publication of an article reviewing the Accordion Pill's unique gastric retention platform in Therapeutic Delivery, highlighting its innovative drug delivery mechanism.
- Did Intec Pharma secure any patents in 2019?
- In May 2019, Intec Pharma was granted a European patent, further protecting its proprietary Accordion Pill technology.
- What was a notable partnership for Intec Pharma in May 2019?
- In May 2019, Intec Pharma announced a research collaboration agreement with Merck, indicating a strategic alliance with a major pharmaceutical company.